Yescarta® (Axicabtagene Ciloleucel) by Fosun Kite Continues Inclusion in 2023 Shanghai Huibao

ShanghaiMay 9, 2023PR Newswire -- On May 9, the Shanghai city-customized commercial supplementary medical insurance "HuHuiBao" 2023Edition pre-sale begins. Fosun Kite Biotechnology Co., Ltd.The first CAR-T cell therapy product in China produced by Fosun Kite Biotechnology Co., Ltd. -- Yikaida® (Axicabtagene Ciloleucel Injection) has gained the trust of the public and official recognition from "Hui Insurance" due to its safe and reliable real-world efficacy. It continues to be included in the 2023 version of "Hui Insurance," supporting the path to a cure for lymphoma patients.

China's First Approved CAR-T Drug, Yikaida® (Axicabtagene Ciloleucel), Included in Shanghai "HuHuiBao"

In recent years, as the number of lymphoma cases in Shanghai has been increasing annually, its characteristics of high incidence, high recurrence rate, difficulty in treatment, and short survival period have become known to more and more citizens. Fortunately, lymphoma is not an incurable disease. With the emergence of the innovative CAR-T cell therapy, the clinical cure rate of lymphoma has significantly improved. In particular, the pioneering launch of Yikaida® has successfully treated over 400 patients with relapsed/refractory large B-cell lymphoma, giving more patients hope for survival.

After the inclusion of Yikaida® in the 2022 “HuHuiBao” coverage directory, it has significantly expedited the process for citizens to access and afford high-quality CAR-T medications.In passing throughWhile CAR-T therapy achieves the expected efficacy,PatientSuccessfully reduced the economic burden of medication and increased treatment confidence with the help of "Hui Huibao" claims. This time, Yikaida® continues to be included in the 2023 version of "Hui Huibao," still following the original policy, which means no restrictions on patients with pre-existing conditions, and eligible patients can receive a maximum compensation of 500,000 yuan.And only 12For just 9 yuan, you can enjoy a total coverage amount of up to 3.1 million.

Since its approval for marketing in June 2021, as the first CAR-T cell therapy product in China, Yikaida® has been recognized for its safety and reliability.Real-world efficacy, gaining widespread recognition from all sectors of society. Successfully established more than 140 Yikai Da® qualified treatment centers across 25 provinces and regions in China, and has been included in over 60 commercial health insurance plans and more than 80 city-level "People's Benefit Insurance" programs in China.

Huang Hai, CEO of Fosun Kite, stated that the continued inclusion of Yikai Da in the 2023 version of "HuHuiBao" will effectively help more lymphoma patients achieve "accessibility and curability," benefiting more citizens in Shanghai. In the future, Fosun Kite will continue to conduct scientific research, fully improve drug quality, and accelerate the market launch of Yikai Da® for its new second-line indication, allowing more patients to benefit as soon as possible.

In the future, with the comprehensive promotion of "Hu Hui Bao", it will continue to play an important supplementary role alongside basic medical insurance, undoubtedly helping more Shanghai residents gain access to high-value innovative drugs and cutting-edge medical technologies.